Oncotarget,
#PaperoftheDay: "Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations…
#PaperoftheDay: "Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations…
UPDATED: Oncotarget's Special Collection on #LungCancer now includes the review paper: "Adjuvant osimertinib treatment in…
#PaperoftheDay: "Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations…
#PaperoftheDay: "Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations…
#PaperoftheDay: "Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations…
#PaperoftheDay: "Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations…
NEW #PaperoftheDay: "Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway…